<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04849065</url>
  </required_header>
  <id_info>
    <org_study_id>IMB-TCIM/ELAII-2019-01</org_study_id>
    <nct_id>NCT04849065</nct_id>
  </id_info>
  <brief_title>Clinical Trial on the Use of Cell Therapy in the Treatment of Patients With Amyotrophic Lateral Sclerosis</brief_title>
  <acronym>TCIM-ELAII</acronym>
  <official_title>Clinical Trial in Phase II of Intramuscular Infusion of Autologous Bone Marrow Stem Cells in Patients With Amyotrophic Lateral Sclerosis.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fundacion para la Formacion e Investigacion Sanitarias de la Region de Murcia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fundacion para la Formacion e Investigacion Sanitarias de la Region de Murcia</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Our working hypothesis is that the injection of autologous bone marrow mononuclear cells&#xD;
      (BMNC) has a positive effect on the natural loss of motor units and on the increase in the&#xD;
      size of the motor unit that occurs in patients with ALS during the evolution of the disease&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Our working hypothesis is that the injection of autologous bone marrow mononuclear cells&#xD;
      (BMNC) has a positive effect on the natural loss of motor units and on the increase in the&#xD;
      size of the motor unit that occurs in patients with ALS during the evolution of the disease.&#xD;
&#xD;
      This hypothesis is based on experimental work done in animal models of ALS and the results of&#xD;
      our previous phase I clinical trial. In this clinical trial (TCIM / ALS, ClinicalTrials.gov&#xD;
      Identifier: NCT02286011) we studied with electrophysiological techniques (in a small number&#xD;
      of patients with ALS) the effects of intramuscular injection of a single dose of BMSC in the&#xD;
      tibialis anterioris (TA) muscle. . The results indicate that this is a safe procedure and&#xD;
      show the presence of a positive and apparently transitory effect on the size and number of&#xD;
      motor units of the TA muscle.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">May 1, 2021</start_date>
  <completion_date type="Anticipated">September 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">May 1, 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Phase II, prospective, multicenter, randomized, parallel, double-blind, placebo-controlled clinical trial</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
    <masking_description>double-blind</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of serious and non-serious adverse events related to the use of bone marrow mononuclear cells in patients with Amyotrophic Lateral Sclerosis</measure>
    <time_frame>48 months from baseline</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>D50 index obtained from stimulus intensity curves</measure>
    <time_frame>48 months from baseline</time_frame>
    <description>This parameter quantifies the number and size of the functional motor units of a given muscle.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Motor unit number index&quot; (MUNIX)</measure>
    <time_frame>48 months from baseline</time_frame>
    <description>The unit amplitude (or area) of the individual motor units are calculated from the amplitude variations (or area) of the muscle action potential obtained in response to stimuli from a fixed intensity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Motor unit size index&quot; (MUSIX)</measure>
    <time_frame>48 months from baseline</time_frame>
    <description>The unit amplitude (or area) of the individual motor units are calculated from the amplitude variations (or area) of the muscle action potential obtained in response to stimuli from a fixed intensity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fiber density (FD)</measure>
    <time_frame>48 months from baseline</time_frame>
    <description>Quantifies the average number of muscle fibers per motor unit. It is obtained from single fiber recordings made with electrodes. The average number of motor unit potentials is calculated in 20 different positions in the muscle.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PAMC amplitude: mV</measure>
    <time_frame>48 months from baseline</time_frame>
    <description>Compound muscle action potential (CMAP)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PAMC area: mV / ms</measure>
    <time_frame>48 months from baseline</time_frame>
    <description>Compound muscle action potential (CMAP)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum force developed in an isometric contraction of the muscles</measure>
    <time_frame>48 months from baseline</time_frame>
    <description>The measurement will be made with a dynamometer during dorsiflexion of the foot (from certain angles) and during abduction of the index finger of the hand, respectively.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fuerza muscular (MRC Medical Research Council) score</measure>
    <time_frame>48 months from baseline</time_frame>
    <description>Muscle strength data will be collected according to the Medical Research Council scale. Muscle strength is graded on a scale of 0 to 5, with 5 being normal muscle strength and 0 being the absence of muscle contraction.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>ALS (Amyotrophic Lateral Sclerosis)</condition>
  <arm_group>
    <arm_group_label>MNC (Mononuclear cells)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MNC (Mononuclear cells) (patients in which stem cells will be injected into the two muscles on one side and placebo -vehicle- in the two contralateral muscles).&#xD;
This group would consist of 74 patients.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Saline</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>(patients in which placebo -vehicle- will be injected into both muscles on both sides). This group would consist of 26 patients.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MNC (Mononuclear cells)</intervention_name>
    <description>Intramuscular infusion of autologous BM CMN into the TA muscle of one of the lower limbs (experimental side)&#xD;
Intramuscular infusion of saline solution (placebo) in the TA muscle of the contralateral lower limb (control side)</description>
    <arm_group_label>MNC (Mononuclear cells)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo / Saline</intervention_name>
    <description>- Intramuscular infusion of saline solution (placebo) in the TA muscle of the contralateral lower limb (control side)</description>
    <arm_group_label>MNC (Mononuclear cells)</arm_group_label>
    <arm_group_label>Saline</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Diagnosis of ALS defined or probable according to the criteria established by the&#xD;
             World Federation of Neurology&#xD;
&#xD;
          -  Age between 18 and 70 years.&#xD;
&#xD;
          -  Patient who offers sufficient guarantees of adherence to the protocol.&#xD;
&#xD;
          -  Neurophysiological data confirming lower motor neuron involvement at the lumbar and&#xD;
             cervical level.&#xD;
&#xD;
          -  Assessment of the motor deficit in the dorsal flexion of both feet (between 3 and 5&#xD;
             points on the MRC scale).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Mellitus diabetes.&#xD;
&#xD;
          -  Other diseases that may be associated with polyneuropathies.&#xD;
&#xD;
          -  Previous history of cerebral stroke.&#xD;
&#xD;
          -  Previous pathology of the peripheral nervous system that affected one or both lower or&#xD;
             upper limbs, with or without clinically evident neurological sequelae.&#xD;
&#xD;
          -  Pregnant or actively breastfeeding patients&#xD;
&#xD;
          -  Patients physiologically capable of becoming pregnant, unless they are using a&#xD;
             reliable contraceptive method (Annex III)&#xD;
&#xD;
          -  Patients with cardiac, renal, hepatic, systemic, immune disease that may influence the&#xD;
             survival of the patient during the test.&#xD;
&#xD;
          -  Positive serology for hepatitis B, hepatitis C or HIV.&#xD;
&#xD;
          -  Clinical and anesthesiological criteria that contraindicate either sedation or the&#xD;
             extraction of BM itself (Alteration of the coagulation system or anticoagulated&#xD;
             patient with inability to withdraw anticoagulation, hemodynamic instability, skin&#xD;
             alteration in the puncture site, etc.)&#xD;
&#xD;
          -  Inclusion in other clinical trials in the last 6 months.&#xD;
&#xD;
          -  Inability to understand informed consent.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Miguel Blanquer Blanquer, MD</last_name>
    <phone>968 36 95 00</phone>
    <email>miguelblanquer@um.es</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hospital Clinico Universitario Virgen de la Arrixaca</name>
      <address>
        <city>Murcia</city>
        <zip>30003</zip>
        <country>Spain</country>
      </address>
    </facility>
    <contact>
      <last_name>Miguel Blanquer Blanquer</last_name>
      <phone>968359767</phone>
    </contact>
    <investigator>
      <last_name>Miguel Blanquer Blanquer, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Carmen Díaz Marín, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Teresa Gavilá Lattur, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>April 15, 2021</study_first_submitted>
  <study_first_submitted_qc>April 15, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 19, 2021</study_first_posted>
  <last_update_submitted>April 15, 2021</last_update_submitted>
  <last_update_submitted_qc>April 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Motor Neuron Disease</mesh_term>
    <mesh_term>Amyotrophic Lateral Sclerosis</mesh_term>
    <mesh_term>Sclerosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

